The study will run over 24 months and include 17 patients suffering from degenerative disc disease, degenerative spondylolisthesis or lumbar spinal stenosis.
Study shows shorter surgical times and hospitalizations, lower readmission rates, and sometimes better patient-reported outcome measures than single people.
Prolonged opioid use was less commonly observed among patients who were either Asian, earned $150,000 or more annually, or had undergone regional anesthesia.
Orthofix's trial is evaluating patients treated for cervical degenerative disc disease at two contiguous vertebral levels with the M6-C disc compared to ACDF.